Inappropriate prescribing for osteoporosis

B E Christopher Nordin, Michael Horowitz and Barry E Chatterton
Med J Aust 2009; 190 (9): . || doi: 10.5694/j.1326-5377.2009.tb02544.x
Published online: 4 May 2009

To the Editor: We believe the current indications for subsidised treatment of osteoporosis specified in the Pharmaceutical Benefits Schedule (PBS) encourage over-prescribing on the one hand, yet, on the other, deny many patients with osteoporosis the treatment they need.

  • B E Christopher Nordin1,2
  • Michael Horowitz1
  • Barry E Chatterton3

  • 1 Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA.
  • 2 SA Health Working Party on Prevention of Osteoporosis and Fractures, Adelaide, SA.
  • 3 Department of Nuclear Medicine and Bone Densitometry, Royal Adelaide Hospital, Adelaide, SA.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.